Moderna and Merck said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence of ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b trial showed.

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

From STAT’s Andrew Joseph: GSK said this morning that it would buy RAPT Therapeutics in a deal worth $2.2 billion, picking up ...

The overall sentiment of these big-money traders is split between 54% bullish and 36%, bearish. Out of all of the special options we uncovered, 11 are puts, for a total amount of $951,480, and 11 are ...

Jan 20 () - Moderna ​and Merck ‌said on ‌Tuesday their experimental vaccine for ⁠a ‌serious type of ‍skin cancer, used in ...